Subtle Medical
Deep learning software that enhances and accelerates medical image acquisition on existing scanners rather than detecting pathology. SubtlePET (FDA cleared 2018) and SubtleMR (2019) denoise and sharpen PET and MRI images, allowing faster and lower dose acquisition; SubtleHD (MR) cleared November 2025 and SubtleHD (PET) cleared May 2026 extend that with newer model architectures, with SubtleHD (PET) supporting all FDA approved radiotracers and, per the vendor, up to 75 percent faster PET imaging. A CT product has clearance pending. The company reports 11 FDA clearances, more than 25 peer reviewed publications, and deployment on more than 1,300 scanners, with customers including Mount Sinai, RadNet, and Radiology Partners. Raised $33 million in growth capital anchored by a Series C led by Morgan Stanley Expansion Capital in 2026.
Capability Axes
Deep learning reconstruction and denoising is the entire product. The software's function is to produce diagnostic quality images from faster or lower dose acquisitions, which is a model output, not a workflow wrapper.
More than 25 peer reviewed publications reported alongside FDA clearance validation, including SubtleHD (PET) validation across a range of accelerated low count acquisitions. Deployment scale is corroborated at more than 1,300 scanners with named customers including Mount Sinai, RadNet, and Radiology Partners. Graded on the existence and depth of peer reviewed evidence; this index does not re verify the underlying studies.
A reported 11 FDA clearances across PET and MR, with product level specificity and dates: SubtlePET in 2018, SubtleMR in 2019, SubtleHD (MR) in November 2025, SubtleHD (PET) in May 2026. A CT product is disclosed as clearance pending rather than described as cleared. Precise, per product, and does not overstate.
Scanner and vendor agnostic by design, compatible with any brand of MRI scanner and PACS, and deployed on existing hardware without new capital equipment. Held back from A because specific data residency and tenancy commitments were not retrieved.
No public pricing. Contact the vendor. Sold through enterprise imaging agreements with no published rate card.
Announced Deployments
Publicly announced health system deployments and partnerships. This is a record of announcements, not an assessment of deployment success or scale.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Contact the vendor
|
Enterprise imaging agreements | — | — | Vendor Published |
Sold through enterprise imaging agreements, typically scoped by scanner or site. No rate card published.